Literature DB >> 10376192

Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects.

H N Hodis1, W J Mack, R M Krauss, P Alaupovic.   

Abstract

Invasive and noninvasive arterial imaging are important techniques used to study atherosclerosis and, specifically, to evaluate the atherogenecity of triglyceride-rich lipoproteins (TRL). Serial coronary angiography trials show significant benefit from lowering low-density lipoprotein cholesterol (LDL-C) which serves to retard lesion progression. Even with aggressive LDL-C reduction, however, up to half of patients demonstrate continued progression of atherosclerosis. Angiographic studies reveal that lowering LDL-C has the most impact on severe lesions, those > or = 50% diameter stenosis, whereas TRL (and their apolipoprotein markers) have been identified as a driving factor behind progression of mild-to-moderate lesions < 50% diameter stenosis. Quantitative coronary angiography (QCA) has demonstrated that progression of mild-to-moderate lesions are among the most significant predictors of clinical coronary events, and that lowering TRL reduces progression of coronary artery disease to the same degree as the lowering of LDL-C.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376192      PMCID: PMC6655859          DOI: 10.1002/clc.4960221404

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  7 in total

1.  Role of LXRs in control of lipogenesis.

Authors:  J R Schultz; H Tu; A Luk; J J Repa; J C Medina; L Li; S Schwendner; S Wang; M Thoolen; D J Mangelsdorf; K D Lustig; B Shan
Journal:  Genes Dev       Date:  2000-11-15       Impact factor: 11.361

2.  Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.

Authors:  Marguerite R Irvin; Edmond K Kabagambe; Hemant K Tiwari; Laurence D Parnell; Robert J Straka; Michael Tsai; Jose M Ordovas; Donna K Arnett
Journal:  Circ Cardiovasc Genet       Date:  2010-08-21

3.  Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.

Authors:  Marguerite R Irvin; Qunyuan Zhang; Edmond K Kabagambe; Rodney T Perry; Robert J Straka; Hemant K Tiwari; Ingrid B Borecki; Lawrence C Shimmin; Colin Stuart; Yu Zhong; James E Hixson; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2012-05       Impact factor: 2.089

4.  Fruit and vegetable consumption and hypertriglyceridemia: Korean National Health and Nutrition Examination Surveys (KNHANES) 2007-2009.

Authors:  C Yuan; H-J Lee; H J Shin; M J Stampfer; E Cho
Journal:  Eur J Clin Nutr       Date:  2015-05-27       Impact factor: 4.016

Review 5.  Metabolic complications associated with HIV protease inhibitor therapy.

Authors:  David Nolan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Hypertriglyceridemia: its etiology, effects and treatment.

Authors:  George Yuan; Khalid Z Al-Shali; Robert A Hegele
Journal:  CMAJ       Date:  2007-04-10       Impact factor: 8.262

7.  Artemisia Iwayomogi Extract Attenuates High-Fat Diet-Induced Hypertriglyceridemia in Mice: Potential Involvement of the Adiponectin-AMPK Pathway and Very Low Density Lipoprotein Assembly in the Liver.

Authors:  Jinhui Lee; Vikram P Narayan; Eun Young Hong; Wan Kyunn Whang; Taesun Park
Journal:  Int J Mol Sci       Date:  2017-08-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.